Opportunities For Phenotypic Screening In Drug Discovery By David C. Swinney Renewed awareness of the value of phenotypic screening to drug discovery creates many new opportunities to increase drug discovery success and productivity. These opportunities include identification of translational phenotypic biomarkers, development of new assays that translate to human disease… Read More
Reconfiguring Drug Discovery Through Innovative Partnerships By Dr Robert Grundy, Iain James, Chas Bountra and Timothy Harrison Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 billion and upwards… Read More
Targeted Chemical Libraries: The keys to unlock the ubiquitin system By Dr Jason Brown and Dr J. Mark Treherne Is novel chemistry the final frontier for ubiquitin system drug discovery? Although the widespread use of target-focused libraries has led to the rapid expansion of novel chemistry as research… Read More
Library Logistics: Managing Comprehensive Compound Collections By Dr Jorg Kroll and David Booth Compound management may seem straightforward but in reality, as the number of new compounds increases dramatically year-on-year, the management of large collections has become increasingly challenging. As highthroughput technologies have become the norm, Bayer HealthCare, a global… Read More
Rules For Drug Discovery: Can simple property criteria help you to find a drug? By Dr Matthew Segall The years since the publication of Lipinski’s Rule of Five (Ro5) (1) in 1997 have seen the growth of a minor industry, dedicated to generating new ‘rules’ for drug discovery. Fuelled by… Read More
Building New Models of Drug Discovery in Europe - The Innovative Medicines Initiative By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman The discovery and development of a new medicine is time-consuming, risky and expensive. It often takes 10-15 years and an investment of on average >$1 billion… Read More
Collaboration For Innovation Is The New Mantra For The Pharmaceutical Industry By Professor Jackie Hunter In order to maintain a flow of innovative medicines there is a growing realisation that companies cannot allow the status quo to remain as it is and the need to identify sources of appropriate knowledge… Read More
More Than Genes and Cells: Drug Discovery in the Extracellular Matrix (ECM) By Dr William Bains Drug discovery in the last few decades has focused on the cellular and genetic mechanisms of disease. This has been very successful in cancer, which is a disease of somatic genetics, and moderately successful… Read More
Large-Scale Expansion of Stem Cells For Therapy and Screening By Dr Y. John Shyu, Dr Katherine E. Strathearn and Dr Richard M. Eglen Recently, pre-clinical and clinical studies of stem cells in regenerative medicine have demonstrated great promise as treatments for various diseases. Their ability to self-renew and differentiate makes… Read More
Partnering with the right CRO is a winning strategy for companies big and small By Dr Davide Molho The Bio-Pharma business model is undergoing radical changes. Over the last two decades, we have seen the biopharmaceutical industry gradually become more willing to look externally and embrace the concept of outsourcing… Read More
Outsourced Kinase Profiling Services: Adding Value To In-House Kinase Programmes Dr John Comley Biochemical kinase profiling using a large panel of kinases with a broad coverage of the human kinome has become the de facto norm within the Pharma industry. The importance of this activity is demonstrated by the large… Read More
Multi-Parameter Flow Cytometry Technology Advances for Rare Cell Analysis and Sorting By David Gebhard and Dr Diether Recktenwald The study of rare cell populations is important to advance medical diagnostics and therapeutics. For many clinical studies, rare cell counts promise to provide valuable alternate end points; examples are circulating tumour… Read More
There are approximately 7,000 rare diseases, which from a regulatory perspective are defined as those diseases where there are less than 200,000 patients in the US or that affect no more than five in 10,000 of the general population in the EU. Such diseases usually have a genetic basis, often… Read More
Carbon-14 Labelled API Manufacturing By Dr Sean L. Kitson and Dr David Speed Carbon-14 labelled API and IMP requirements for Phase 0/I to Phase III mass balance and micro-dosing clinical trials can be met by contract manufacturing in compliance with MHRA and FDA Phase I cGMP guidelines. The short supply… Read More
Fragment Library Design - The Evolution Of Fragment Based Lead Discovery By Dr Edward Zartler, Dr Chris Swain and Simon Pearce With the growing need to streamline the drug discovery process, screening against fragment libraries rather than drug-like molecules has become increasingly adopted as an integral part of many drug… Read More
The Challenges Of The Changing Drug Discovery Model By Dr Mark Downs and Dr Tom Blackburn The drug development industry is restructuring worldwide. This brings different ways of working and new challenges. As the industry moves away from internally focused research to an external model, project management and communication of… Read More